Advancing Evidence Generation
Through HTA for Enhanced Health Outcomes:
A Global Perspective

### **Student Network Session**


ISPOR Europe 2024

#### Fang-Ju (Irene) Lin, PhD

Associate Professor, School of Pharmacy, College of Medicine, National Taiwan University (NTU)

Deputy Director, Department of Pharmacy, NTU Hospital, Taiwan





# **Health Technology Assessment (HTA)**

- What is HTA?
  - Multidisciplinary process evaluating the medical, social, economic and ethical aspects related to the use of a health technology in a systematic, transparent, unbiased, and robust manner --- Appl Health Econ Health Policy 2021;19(3):281-304.
  - "HTA is a multidisciplinary process that uses explicit methods to determine the VALUE of a health technology at different points in its lifecycle. The purpose is to inform decision making in order to promote an equitable, efficient, and high-quality health system." --- International Network of Agencies for HTA (INAHTA)
- Considers a wide range of factors, including clinical efficacy, patient outcomes, costeffectiveness, budget impact, ethical considerations, and social implications
- Involves multiple stakeholders, including healthcare professionals, patients, industry representatives, and policymakers

# Why do we need health technology assessment (HTA)?

Evidence-based decision-making (adoption, reimbursement & use)

Resource allocation & cost containment

Patient safety and quality of care


Equity & access

Regulatory approval	HTA (to inform reimbursement decisions)
Provide market authorization	Support for clinical and coverage decisions within a particular healthcare system
Evaluate whether the clinical benefits outweigh the risks  Should this technology be available?	Evaluate whether the technology offers useful, appropriate (and affordable) benefits for all or a select subgroup of patients in the particular healthcare system compared to what is most commonly used in the disease area
Safety, efficacy, quality (e.g., GMP)	(Comparative) effectiveness, safety, quality of life, economics, budget impact, social, ethical, legal, organizational
Characteristics of studies they prioritize	
Placebo (when no head-to-head comparison)	Active control, ideally standard of care
Surrogate endpoints	Final clinical "hard" outcomes such as death; quality of life
Trial duration	Lifetime or at minimum the time needed to capture all risks and benefits of therapy
	Provide market authorization  Evaluate whether the clinical benefits outweigh the risks  Should this technology be available?  Safety, efficacy, quality (e.g., GMP)  Eudies they prioritize  Placebo (when no head-to-head comparison)  Surrogate endpoints

# Arriving at an HTA recommendation (health technology assessment)

#### **Evidence review and synthesis**

- Clinical outcome studies
- Economic information




- ✓ No reimbursement (do not list)
- ✓ Conditional reimbursement (list with restrictions)

#### **Pricing decisions**

Access restrictions for sub-populations or sub-indications

Adapted from Teutsch, S., Berger, M. (2005). 'Evidence synthesis and evidence-based decision making; Related but distinct processes. *Medical Decision Making*, pp. 487-489.

# Process for listing in the NHI Pharmaceutical Benefits and Reimbursement Scheme (PBRS) in Taiwan (simplified version)



With mechanisms to notify HTD, receive feedback/response, and negotiation regarding agreement

# How to determine the value of health technology?

## Components of HTA application dossier or 'submission'

- Burden of disease
- Description of medicine/technology
- Clinical evidence: Efficacy, effectiveness & safety (comparative)
- Economic evidence: Cost-effectiveness analyses & budget Impact analyses
- Assessments of social, ethical, and legal implications


## **Methodologies for HTA**

- Randomized controlled trials (RCTs)
- Systematic reviews, meta-analyses, network meta-analyses
- Real-world evidence from observational studies and registries
- Patient-reported outcomes
- Cost-effectiveness analysis & economic models projecting long-term costs and outcomes
- Budget impact analysis

## **Evaluation Criteria Considered in HTA**

- Criteria that are more common for HTA among different agencies: efficacy or effectiveness, safety, cost-effectiveness, and budget impact
- Some of the criteria are more qualitative than others (e.g., equity, legal, and public health aspects)
  - Included in the appraisal part of HTA rather than the evaluation part
  - Implicit or ad hoc rather than explicit and systematic
- Unexplained heterogeneity of coverage decisions across countries
  - Different budget constraints and national priorities, inconsistencies in medicines' eligibility for reimbursement
  - Different HTA processes and methodological frameworks adopted
  - Additional value concerns beyond economic evaluation or clinical benefit assessment are captured to a different extent in the process

### **Elements of Value**



Green circles: core elements of value

Light blue circles: common but inconsistently used elements of value

Dark blue circles: potential novel elements of value

Blue line: value element included in traditional payer or health plan perspective

Red line: value element also included in societal perspective

# **Evolving HTA activities in Taiwan**

- Patient involvement
  - Patients engaged in HTA and reimbursement decision-making processes (since 2015)
  - Educational programs for patients and caregivers (since 2016)
- International collaboration
  - Actively participate in HTA networks, such as HTAsiaLink, ISPOR, and HTAi
  - Partnered with UK's NICE for knowledge exchange (since 2023)
- Process improvement
  - Implement a parallel review process to reduce time for new technology inclusion
  - Expand the use of real-world evidence (RWE) in decision-making
  - Introduce provisional listing for selected new drugs and indications
  - Conduct health technology reassessments (HTR)

#### If you're interested in this field, what can you start to do?

- Gain a solid foundation in healthcare and related disciplines
  - Understanding healthcare systems, epidemiology, clinical research methods, health economics, health policy
  - Evidence generation (technical skills such as data management, statistical analysis, & economic modeling)
  - Critical appraisal of scientific literature and evidence synthesis
- Consider pursuing advanced degrees or certifications
- Learn about HTA concepts, methods, organizations, and related guidance
- Participate in training programs and workshops
- Gain practical experience through internships or research projects
- Stay updated with the latest research and developments

